Covid-19 and SARS-CoV-2 Detection in the Conjunctiva: Meta Analysis
October 19, 2022S2, EP6 Atrial Fibrillation with Dr. Paul Wang, Stanford
March 2, 2023Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test for influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19.
The Lucira COVID-19 & Flu Home Test is a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes.
The Lucira COVID-19 & Flu Home Test is a single use test and can be purchased without a prescription and performed completely at-home using nasal swab samples. Self collection can be done by people ages 14 and older. For people 2 years to age 13 years, an adult can help with the test.
The test works by swirling the sample swab in a vial that is placed in the test unit. In 30 minutes or less, the test unit will display the results that show whether a person is positive or negative for each of the following: Influenza A, Influenza B and COVID-19. Individuals should report all results obtained to their doctor or healthcare team.
In patients with symptoms, the Lucira COVID-19 & Flu Home Test correctly identified 99.3% of negative Influenza A samples and 90.1% of positive Influenza A samples. It identified 100% of negative and 88.3% of positive COVID-19 samples and 99.9% of negative Influenza B samples. The Emergency Use Authorization Act (EUA) requires Lucira to continue to collect samples to study the test’s ability to detect Influenza B in real-world settings.
Individuals who test positive for either flu or COVID-19 should take appropriate precautions to avoid spreading the virus and should seek follow-up care with their physician. Additional testing may be necessary.
